"CKM Syndrome" Defines a Very Wide Target and Medicine is Ready, Says Chiadi Ndumele, MD, PhD, MHS
Ndumele chairs the American Heart Association committee that characterized the syndrome and wrote the statement of evidence for its assessment and management.
The disease entity cardiovascular metabolic kidney syndrome, aka CKM syndrome, owes its naming to a tipping point in the medical and scientific communities' deepening appreciation for the connections among the diseases and for their combined impact on cardiovascular mortality.
Dr Chiadi Ndumele, associate professor of medicine and director of obesity and cardiometabolic research in the division of cardiology at Johns Hopkins University, is chair of the writing committee for the American Heart Association's new scientific statement on prevention and management of CKM syndrome. In a recent interview with Patient Care,® he also pointed to the growing number of therapeutic options with both cardio- and renoprotective properties as contributing to the optimism behind the statement and the tools it introduces to help identify and manage individuals at all levels of risk. He explains more in this short video
Chiadi Ndumele, MD, PhD, MHS, is associate professor of medicine and director of obesity and cardiometabolic research in the division of cardiology at Johns Hopkins University. His research focuses on the relationship between obesity and cardiovascular disease, and particularly heart failure.
